Med24
diabetes 15. 10. 2026 • 2 min read • U.S. Food and Drug Administration (OpenFDA)

Tacrolimus: FDA Clinical Pharmacology, Indications and Prescribing Update

1 INDICATIONS AND USAGE Tacrolimus capsules are a calcineurin-inhibitor immuno-suppressant indicated for the prophylaxis of organ rejection in adult and pediatric patients receiving allogeneic liver, kidney, or heart transplants, in combination with other immunosuppressants. ( 1.1 ) 1.1 Prophylaxis of Organ Rejection...

Addressing Post-Intensive Care Syndrome Among Survivors of COVID (APICS-COVID)

Tacrolimus capsules, manufactured by Panacea Biotec Limited, are an immunosuppressant indicated for the prophylaxis of organ rejection in adult and pediatric patients receiving allogeneic liver, kidney, or heart transplants. The medication is used in combination with other immunosuppressants.

Mechanism of Action and Pharmacokinetics

Tacrolimus inhibits calcineurin, preventing the dephosphorylation and translocation of factors like NF-AT and NF-κB, thereby suppressing cytokine expression including IL-1 beta, IL-2, and TNF-alpha. This results in the inhibition of T-lymphocyte activation and proliferation. Pharmacokinetic data indicates that whole blood concentrations are more appropriate than plasma concentrations for describing tacrolimus activity.

Sponsored content

Common Adverse Reactions and Dosage

In kidney transplant trials (N=412), the most common adverse reactions (≥30%) included infection, tremor, hypertension, abnormal renal function, constipation, diarrhea, headache, abdominal pain, insomnia, nausea, hypomagnesemia, urinary tract infection, hypophosphatemia, peripheral edema, asthenia, pain, hyperlipidemia, hyperkalemia, and anemia. Nephrotoxicity was reported in approximately 52% of kidney transplant patients. Dosage adjustments are recommended for African-American patients, and those with hepatic or renal impairment. Initial oral dosages range from 0.2 mg/kg/day to 0.3 mg/kg/day, divided into two doses every 12 hours, depending on the organ transplant type. Therapeutic drug monitoring is recommended. Patients should avoid grapefruit consumption. The medication’s effectiveness is dependent on consistent administration.

Original Scientific Source
U.S. Food and Drug Administration (OpenFDA)
View Original Source
Medical Disclaimer All calculations, recommendations, and interpretations provided by this tool are for informational and educational purposes only. They do not substitute professional medical advice, diagnosis, or treatment. Always consult your physician regarding any health concerns.

Recommended Medical News

All news →
Advertisement